On Wednesday, JMP Securities reiterated its Market Outperform rating and $7.00 price target for Esperion Therapeutics (NASDAQ:ESPR) stock, which currently has a market capitalization of $433 million. According to InvestingPro data, analyst targets for the stock range from $2.05 to $16.00, reflecting diverse views on the company’s potential. The affirmation follows recent commentary by the company’s Vice President of Clinical Development, LeAnne Bloedon, and Dr. Patrick Moriarty, MD, during a key opinion leader (KOL) event hosted by Esperion the day before.
At the event, Bloedon reinforced the efficacy and safety profile of the company’s drug NEXLETOL/NEXLIZET. She presented data from clinical trials involving almost ten thousand patients treated with bempedoic acid, some for a period of up to six years. The findings indicated that the drug was well-tolerated and exhibited safety comparable to a placebo. This clinical success has contributed to Esperion’s impressive revenue growth of 187% over the last twelve months, as reported by InvestingPro.
Dr. Moriarty, who has extensive experience in lipid lowering therapy clinical trials, including those for statins, shared insights from his work at the lipid clinic in Kansas. He underscored the significance of having effective non-statin lipid-lowering therapies available, especially for patients who are intolerant to statins. Dr. Moriarty pointed out the unique aspects of bempedoic acid and its role in cardiovascular risk reduction.
JMP Securities analyst Jason N. Butler highlighted the growing real-world clinical validation of bempedoic acid’s global use. His positive outlook for Esperion Therapeutics is supported by a risk-adjusted, discounted cash flow (DCF) analysis, which underpins the $7 price target for the company’s shares.
Esperion Therapeutics focuses on developing and commercializing therapies to lower lipid levels in patients with elevated low-density lipoprotein cholesterol (LDL-C). With the continued validation of bempedoic acid, Esperion aims to address the needs of patients who cannot tolerate traditional statin therapies. While the company maintains a healthy gross profit margin of 64%, InvestingPro analysis indicates it is not yet profitable over the last twelve months. The KOL event and the subsequent reiteration of JMP Securities’ rating and price target provide a clear view of the company’s position and the perceived potential of its lead drug candidate. Subscribers to InvestingPro can access detailed financial health metrics and 6 additional ProTips for deeper insight into Esperion’s investment potential.
In other recent news, Esperion Therapeutics has been making significant financial maneuvers. The company has issued $100 million in new convertible notes, secured a $150 million loan, and provided an update on its expected operating expenses for the fiscal year ending December 31, 2025. The projected research and development costs are between $55 million to $65 million, and selling, general, and administrative expenses are expected to range from $160 million to $170 million.
Goldman Sachs resumed its coverage of Esperion, assigning a Neutral rating. Cantor Fitzgerald initiated coverage with an Overweight rating, and H.C. Wainwright maintained a Buy rating for the company. These ratings reflect the recent strategic moves and financial performance of Esperion.
The company’s third quarter of 2024 financial performance showed a 53% year-over-year increase in U.S. net product revenue, totaling $31.1 million, and a total revenue rise to $51.6 million. These financial results underscore Esperion’s ongoing efforts to expand its global reach and enhance its product offerings.
Esperion also secured a licensing agreement with Neopharm Israel, granting exclusive rights to commercialize its cardiovascular drugs NEXLETOL and NEXLIZET in Israel, Gaza, and the West Bank. This aligns with the company’s broader international growth strategy.
These recent developments reflect Esperion’s strategic efforts to strengthen its financial position, manage operating expenses, and expand its market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.